vs
AC Immune SA（ACIU）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
硕腾的季度营收约是AC Immune SA的1661.6倍（$2.4B vs $1.4M）。硕腾净利率更高（25.3% vs -1622.4%，领先1647.7%）。AC Immune SA同比增速更快（90.1% vs 3.0%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
ACIU vs ZTS — 直观对比
营收规模更大
ZTS
是对方的1661.6倍
$1.4M
营收增速更快
ACIU
高出87.1%
3.0%
净利率更高
ZTS
高出1647.7%
-1622.4%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $2.4B |
| 净利润 | $-23.3M | $603.0M |
| 毛利率 | — | 70.2% |
| 营业利润率 | -1484.5% | 31.9% |
| 净利率 | -1622.4% | 25.3% |
| 营收同比 | 90.1% | 3.0% |
| 净利润同比 | 6.9% | 3.8% |
| 每股收益（稀释后） | — | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUZTS
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | $1.4M | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | $755.7K | $2.4B | ||
| Q1 24 | — | $2.2B |
净利润ACIUZTS
| Q4 25 | — | $603.0M | ||
| Q3 25 | — | $721.0M | ||
| Q2 25 | $-23.3M | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | — | $682.0M | ||
| Q2 24 | $-25.0M | $624.0M | ||
| Q1 24 | — | $599.0M |
毛利率ACIUZTS
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
营业利润率ACIUZTS
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | -1484.5% | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | -3051.1% | 33.0% | ||
| Q1 24 | — | 34.1% |
净利率ACIUZTS
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | -1622.4% | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | — | 28.6% | ||
| Q2 24 | -3313.0% | 26.4% | ||
| Q1 24 | — | 27.4% |
每股收益（稀释后）ACIUZTS
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | — | $1.50 | ||
| Q2 24 | — | $1.37 | ||
| Q1 24 | — | $1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $82.2M | $3.3B |
| 总资产 | $209.2M | $15.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACIUZTS
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $28.3M | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | $56.7M | $1.6B | ||
| Q1 24 | — | $2.0B |
股东权益ACIUZTS
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | $82.2M | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $135.8M | $5.0B | ||
| Q1 24 | — | $5.1B |
总资产ACIUZTS
| Q4 25 | — | $15.5B | ||
| Q3 25 | — | $15.2B | ||
| Q2 25 | $209.2M | $14.5B | ||
| Q1 25 | — | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | — | $14.4B | ||
| Q2 24 | $261.3M | $14.2B | ||
| Q1 24 | — | $14.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $893.0M |
| 自由现金流经营现金流 - 资本支出 | — | $732.0M |
| 自由现金流率自由现金流/营收 | — | 30.7% |
| 资本支出强度资本支出/营收 | — | 6.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | — | $2.3B |
8季度趋势，按日历期对齐
经营现金流ACIUZTS
| Q4 25 | — | $893.0M | ||
| Q3 25 | — | $938.0M | ||
| Q2 25 | — | $486.0M | ||
| Q1 25 | — | $587.0M | ||
| Q4 24 | — | $905.0M | ||
| Q3 24 | — | $951.0M | ||
| Q2 24 | — | $502.0M | ||
| Q1 24 | — | $595.0M |
自由现金流ACIUZTS
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
自由现金流率ACIUZTS
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
资本支出强度ACIUZTS
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
现金转化率ACIUZTS
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACIU
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
